The Rise of a New Eugenics
By Lloyd Lewis and Julie Reiskin,
Denver Post
| 07. 04. 2013
Eugenics was a disturbing sociopolitical movement in the early 20th century that promoted reproduction of the "fittest" and limited reproduction of the "unfit" with "inferior" genes. It took root in academia, influenced a famous Supreme Court decision, and resulted in the forced sterilization of tens of thousands of mentally ill or mentally challenged women in this country.
Adolf Hitler's embrace of eugenics would discredit the movement, but unfortunately it didn't disappear. Today, in fact, we see the rise of a new eugenics, made possible by the rapid development of bioscience and biotechnology, especially from the mapping of the human genome.
We now have researchers with the scientific know-how working with Wall Street-backed corporations to develop the new weapon in the struggle to rid the world of people with developmental disabilities: a "non-invasive prenatal test (NIPT)" that can detect a "disability" or "genetic disorder" anywhere from the fifth to ninth week of pregnancy without amniocentesis. One of the first "disorders" targeted by NIPT technologies is Down syndrome (DS). Although this test is sometimes promoted for "women at risk" for having children...
Related Articles
By Timnit Gebru and Émile P. Torres, First Monday | 04.14.2024
The stated goal of many organizations in the field of artificial intelligence (AI) is to develop artificial general intelligence (AGI), an imagined system with more intelligence than anything we have ever seen. Without seriously questioning whether such a system can...
By Harold Brubaker, The Philadelphia Inquirer | 04.04.2024
Acompany started by University of Pennsylvania scientist Jim Wilson has received FDA approval to test a form of gene editing in infants for the first time in the United States, the company said Thursday.
The Plymouth Meeting company, iECURE, is...
By Jason Kehe, Wired | 04.11.2024
God help the babies! Or, absent God, a fertility startup called Orchid. It offers prospective parents a fantastical choice: Have a regular baby or have an Orchid baby. A regular baby might grow up and get cancer. Or be born...
By Nick Paul Taylor, BioSpace | 03.14.2024
A U.K. watchdog balked at the cost-effectiveness of Vertex Pharmaceuticals’ CRISPR-based sickle cell disease therapy Thursday, recommending against funding the treatment unless uncertainties can be cleared up satisfactorily.
The U.K. became the first country to authorize Vertex’s Casgevy (exagamglogene...